Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
In recent years, the nuclear medicine and imaging communities have focused attention on the development of ?molecular
imaging agents? for identification of target-rich sites that purport a relationship to clinically relevant parameters. For example,
elevated expression levels of numerous protein biomarkers like epidermal growth-factor receptor (EGFR), Her2/
prostate-specific membrane antigen (PSMA) have been validated as imaging/therapeutic targets for various cancers. Yet in spite
of much preclinical success, translation of new imaging agents has been slow, and the clinical value of such radiotracers remains
While the repertoire of targeted chemotherapies for cancer continues to expand rapidly, there are virtually no non-
invasive technologies that measure the degree of signaling through oncogenic pathways. In this presentation, we explore how
an understanding of clinical requirements helped reshape our initial radiotracer program. From a foundation in the design of
targeted molecular imaging agents with zirconium-89 radiolabelled monoclonal antibodies for monitoring therapy, we discover
how a combination of new and old technologies can be exploited to produce the next generation of radiotracers reporting on
functional oncogenic signaling status.
Jason P. Holland completed his doctorate in Inorganic, Computational and Radiochemistry at the University of Oxford, UK in 2008. He trained as
a Post-doctoral Scholar at Memorial Sloan-Kettering Cancer Center, New York, in the laboratory of Prof. Jason S. Lewis and as a Senior Fellow
the ETH Zurich in Switzerland. He was appointed Assistant Chemist in 2012 at Massachusetts General Hospital, Harvard Medical School. He has
published more than 50 research papers and serves on the editorial board of several journals including the
Journal of Nuclear Medicine
. His research
concentrates on the development and translation of new metal-based radiopharmaceuticals for PET imaging in oncology.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals